1. 22Rv1 prostate cancer cells were treated with enzalutamide to generate resistant cells (22Rv1-R). 2. Microscopy showed no morphological differences between 22Rv1 and 22Rv1-R cells. Western blot analysis revealed higher MDR1 expression in 22Rv1-R cells. 3. MTT assay demonstrated 22Rv1-R cell viability remained stable in increasing enzalutamide concentrations, indicating resistance, while 22Rv1 cell viability decreased.